Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Calvin Chao

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Clinical Breast Cancer|December 11, 2013
Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancerHideko Yamauchi, Chizuko Nakagawa, Hiroyuki Takei, et al.
The Oncologist|January 27, 2018
Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, CanadaSofia Torres, Maureen Trudeau, Sonal Gandhi, et al.
Journal of Gastrointestinal Oncology|March 14, 2022
Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatinGreg Yothers, Alan P Venook, Eiji Oki, et al.
Cancers|May 14, 2025
Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated CancersCatherine H Marshall, Ali T Arafa, Ellen Jaeger, et al.
BMC Health Services Research|September 6, 2014
Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in JapanHideko Yamauchi, Chizuko Nakagawa, Shinji Yamashige, et al.
Breast Cancer Research : BCR|April 1, 2017
Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65Suzanne C O'Neill, Claudine Isaacs, Filipa Lynce, et al.
Cancer|August 21, 2015
Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 yearsArnold L Potosky, Suzanne C O'Neill, Claudine Isaacs, et al.
Journal of Surgical Oncology|October 8, 2014
A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospitalJuan Enrique Bargallo, Fernando Lara, Robin Shaw-Dulin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 21, 2015
Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 YearsSuzanne C O'Neill, Claudine Isaacs, Calvin Chao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2025
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast CancerChang-Ching A Lin, María Rosario Chica-Parrado, Nisha Unni, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Clinical Breast Cancer|December 11, 2013
Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancerHideko Yamauchi, Chizuko Nakagawa, Hiroyuki Takei, et al.
The Oncologist|January 27, 2018
Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, CanadaSofia Torres, Maureen Trudeau, Sonal Gandhi, et al.
Journal of Gastrointestinal Oncology|March 14, 2022
Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxaliplatinGreg Yothers, Alan P Venook, Eiji Oki, et al.
Cancers|May 14, 2025
Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated CancersCatherine H Marshall, Ali T Arafa, Ellen Jaeger, et al.
BMC Health Services Research|September 6, 2014
Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in JapanHideko Yamauchi, Chizuko Nakagawa, Shinji Yamashige, et al.
Breast Cancer Research : BCR|April 1, 2017
Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65Suzanne C O'Neill, Claudine Isaacs, Filipa Lynce, et al.
Cancer|August 21, 2015
Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 yearsArnold L Potosky, Suzanne C O'Neill, Claudine Isaacs, et al.
Journal of Surgical Oncology|October 8, 2014
A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospitalJuan Enrique Bargallo, Fernando Lara, Robin Shaw-Dulin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 21, 2015
Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 YearsSuzanne C O'Neill, Claudine Isaacs, Calvin Chao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2025
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast CancerChang-Ching A Lin, María Rosario Chica-Parrado, Nisha Unni, et al.
Pageof 4